Vanguard Group's 13G/A Filing for Maravai LifeSciences Holdings

The Vanguard Group filed a Schedule 13G/A amendment for Maravai LifeSciences Holdings Inc, reporting ownership of 7,125,498 shares, representing 4.92% of the company's common stock. The filing indicates that Vanguard holds these shares on behalf of its clients, including investment companies and managed accounts. The shares are held in the ordinary course of business and not for the purpose of influencing control of the issuer. The filing was signed by Ashley Grim, Head of Global Fund Administration, on October 31, 2025.